ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "chemokines"

  • Abstract Number: 2284 • 2016 ACR/ARHP Annual Meeting

    Differential Effect of MSU-Crystal Induced Inflammation on Macrophage Polarization

    Rashid Ahmed1, Nicole Yang2, Changqi Sun3 and Anthony M. Reginato3, 1Rhode Island Hospital, The Warren Alpert School of Medicine at Brown University, Providence, RI, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, USA., Boston, MA, 3Division of Rheumatology, Rhode Island Hosital/The Warren Alpert School of Medicine of Brown University, Providence, RI

    Background/Purpose:  Gouty arthritis is a common inflammatory joint disease that arises in response to the deposition of monosodium urate (MSU) crystals in soft joints, periarticular…
  • Abstract Number: 2432 • 2016 ACR/ARHP Annual Meeting

    Immune Abnormalities Leading to Exaggerated Production of IFN-Gamma (IFNγ) and the Therapeutic Response to an Anti-IFNγ Antibody in a Patient with NRLC4 Mediated Disease

    Claudia Bracaglia1, Giusi Prencipe2, Manuela Pardeo1, Geneviève Lapeyre3, Emiliano Marasco2, Antonella Insalaco1, Walter Ferlin3, Robert Nelson3, Cristina de Min3 and Fabrizio De Benedetti1, 1Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, 2Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy, 3NovImmune S.A., Geneva, Switzerland

    Background/Purpose: Animal and human data suggest that IFNγ plays a pathogenic role in HLH. A phase 2 trial with the anti-IFNγ monoclonal antibody NI-0501 in…
  • Abstract Number: 3036 • 2016 ACR/ARHP Annual Meeting

    IL-22 Is Dysregulated in Psoriatic Arthritis and Acts to Limit IFN-γ Driven Inflammatory Chemokine Production

    Amara Ezeonyeji1, Helen Baldwin2, Milica Vukmanovic-Stejic3 and Michael R. Ehrenstein4, 1Rheumatology, Medicine, University College London, London, United Kingdom, 2Rheumatology, Centre for Rheumatology Research, University College London, london, United Kingdom, 3Infection & Immunity, University College London, london, United Kingdom, 4Medicine, University College London, London, United Kingdom

    Background/Purpose: IL-22 is an IL-10 family cytokine with both pro-inflammatory and anti-inflammatory effects and its dysregulation is associated with the development of autoimmune disease including…
  • Abstract Number: 72 • 2016 ACR/ARHP Annual Meeting

    Longitudinal Expression of CXCL10 in Psoriasis Patients That Develop Psoriatic Arthritis

    Fatima Abji1, Remy Pollock2, Kun Liang3, Vinod Chandran4 and Dafna D Gladman5, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, 4Rheumatology, University of Toronto, Toronto, ON, Canada, 5University of Toronto, Toronto, ON, Canada

    Longitudinal Expression of CXCL10 in Psoriasis Patients that Develop Psoriatic Arthritis Patients Fatima Abji1, Remy Pollock1 Kun Liang2, Vinod Chandran1,3, Dafna D. Gladman1,3 1University of…
  • Abstract Number: 272 • 2016 ACR/ARHP Annual Meeting

    Interferon Chemokine Score and Other Cytokine Measures Predict Changes in Disease Activity in Patients with Juvenile and Adult Dermatomyositis

    Cynthia S. Crowson1, Jeannette M. Olazagasti Lourido2, Molly S. Hein3, Richard S. Pendegraft4, Michael A. Strausbauch5, Timothy B. Niewold6, Floranne C. Ernste7, Theresa L. Wampler Muskardin3, Erik J. Peterson8, Emily C. Gillespie9 and Ann M Reed10, 1Health Sciences Research, Mayo Clinic, Rochester, MN, 2University of Puerto Rico, San Juan, Puerto Rico, 3Rheumatology, Mayo Clinic, Rochester, MN, 4Biomedical Statistics and informatics, Rochester, MN, 5Surgical Research, Mayo Clinic, Rochester, MN, 6Rheumatology and Immunology, Mayo Clinic, Rochester, MN, 7Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, 8Center for Immunology/Department of Medicine, University of Minnesota, Minneapolis, MN, 9Medicine, University of Minnesota, Minneapolis, MN, 10Rheumatology, Duke University, Durham, NC

    Background/Purpose:   Methods:  Multiplexed immunoassays (Meso Scale Discovery) enabled simultaneous measurement of IFN-regulated chemokines and other pro- and anti-inflammatory cytokines specific to differentiation of specific…
  • Abstract Number: 829 • 2016 ACR/ARHP Annual Meeting

    High Level of Chemokine CCL2 Is Associated with Lung Fibrosis Progression and Reduced Survival in Two Independent Systemic Sclerosis Cohorts

    Anna Hoffmann-Vold1, Richard Huyen2, Elizabeth R. Volkmann2, Oyvind Midtvedt1, Vyacheslav Palchevskiy2, May Brit Lund3, Torhild Garen1, Trond Mogens Aalokken4, Anders Heiervang Tennøe1, Stephen Samuel Weigt2, Mike Shino2, Rajan Saggar5, David Ross2, Joseph Lynch III2, Thor Ueland6, Michael Fishbein7, Pål Aukrust8, Øyvind Molberg1 and John A Belperio2, 1Rheumatology, Oslo University Hospital, Oslo, Norway, 2University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 3Respiratory Medicine, Oslo University Hospital, Oslo, Norway, 4Radiology, Oslo University Hospital, Oslo, Norway, 5Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 6Research, Oslo University Hospital, Oslo, Norway, 7Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA, 8Research Intitute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway

    Background/Purpose:  Markers for early identification of progressive interstitial lung disease (ILD) in systemic sclerosis (SSc) are in demand. The proto-typical inflammatory chemokine CCL2 has been linked…
  • Abstract Number: 1120 • 2016 ACR/ARHP Annual Meeting

    Interleukin-1β Stabilize CXCL2 mRNA and Increase Its Expression

    Satoshi Yamasaki, Yusuke Yoshida and Eiji Sugiyama, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan

    Background/Purpose: Changes in gene expression are closely related to inflammation and joint destruction in RA. Recently, it has been recognized that post-transcriptional regulation of the…
  • Abstract Number: 13L • 2015 ACR/ARHP Annual Meeting

    Safety and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study in Rheumatoid Arthritis

    Yoshiya Tanaka1, Tsutomu Takeuchi2, Hisanori Umehara3, Toshihiro Nanki4, Hideto Akama5, Nobuyuki Yasuda5, Fumitoshi Tago5, Makoto Kawakubo5, Seiichiro Hojo5, Tetsu Kawano6 and Toshio Imai6, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2Dept. of Internal Medicine, School of Medicine Keio University, Tokyo, Japan, 3Kyoto University Graduate School of Medicine, Kyoto, Japan, 4School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, 5EISAI Co. Ltd., Tokyo, Japan, 6KAN Research Institute, Inc., Kobe, Japan

    Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
  • Abstract Number: 87 • 2015 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis (RA) Risk Gene CCR6 Polymorphism: Drug-Induced “Reversal” of ER Binding and the Expression of Inflammatory Mediators -Potential Molecular Mechanism Links Between Estrogen and RA

    Ming-Fen Ho1, Richard M. Weinshilboum2, Liewei Wang2, James N. Ingle3 and Tim Bongartz4, 1Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Rochester, Rochester, MN, 2Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, 3Department of Medical Oncology, Mayo Clinic, Rochester, MN, 4Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose: The rheumatoid arthritis (RA) risk locus CCR6 SNP rs3093024, is in tight linkage disequilibrium with rs3093023 which has been associated with RA risk. RA…
  • Abstract Number: 905 • 2015 ACR/ARHP Annual Meeting

    Citrullinated Epithelial-Derived Neutrophil-Activating Peptide 78 (ENA-78/CXCL5) Induces Monocyte Migration Via JNK and NFκB Signaling Pathways

    Ray A. Ohara1, Nicholas Lepore2, W. Alexander Stinson3, Gautam Edhayan3, Phillip L. Campbell1, Sarah Arwani1, Rachel Morgan1, Jeffrey H. Ruth1, Alisa E. Koch1,4, David A. Fox1 and M. Asif Amin1, 1Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 2University of Michigan, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 3Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 4Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by monocyte (MN) infiltration into the synovium. Citrullination is a post-translational modification of arginine to…
  • Abstract Number: 1139 • 2015 ACR/ARHP Annual Meeting

    Differential Inflammatory Profile in Experimental Models of Arthritis

    Ana C. Ortiz1, Anne Crilly1, Lynette Dunning1, Carmen Huesa1, C. S. Goodyear2, John C. Lockhart1, William R. Ferrell2 and Iain B. McInnes2, 1Institute of Biomedical and Environmental Health Research, University of the West of Scotland, Paisley, United Kingdom, 2Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: While osteoarthritis (OA) in humans is characterized by cartilage degradation, osteophyte formation and joint remodeling, inflammation and synovitis are now recognized to contribute to…
  • Abstract Number: 1148 • 2015 ACR/ARHP Annual Meeting

    The Role of TRPC6 in CXCR2-Mediated Chondrocyte Phenotypic Stability

    Joanna Sherwood1, Jessica Bertrand1, Francesco Dell'Accio2 and Thomas Pap3, 1Institute for Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany, 2EMR, Queen Mary's School of Medicine and Dentistry, London, United Kingdom, 3Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany

    Background/Purpose: We have recently demonstrated that ELR+ CXC chemokines signaling via the CXCR2 receptor, are produced by healthy chondrocytes and are retained within the cartilage…
  • Abstract Number: 1361 • 2015 ACR/ARHP Annual Meeting

    Synovial Macrophages Promote TGF-β Signaling but Protect Against Influx of S100A8/S100A9-Producing Cells after Intra-Articular Injections of Oxidized Low-Density Lipoproteins

    Wouter de Munter1, Martijn H. van den Bosch1, Arjen Blom1, Birgitte Walgreen2, Monique Helsen1, Leo Joosten3, Johannes Roth4, Thomas Vogl5, Fons van de Loo1, Marije Koenders1, Wim van den Berg1, Peter van der Kraan1 and Peter van Lent1, 1Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 2Experimentel Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 3Internal Medicine, Radboud university medical center, Nijmegen, Netherlands, 4Institute of Immunology, University of Münster, Münster, Germany, 5University of Muenster, Muenster, Germany

    Background/Purpose:  In previous studies we found that synovial macrophages regulate joint pathology during experimental osteoarthritis (OA). Recently, we found that high systemic levels of LDL…
  • Abstract Number: 1911 • 2015 ACR/ARHP Annual Meeting

    Monocyte Chemoattractant Protein-1 (MCP-1, CCL2) Is a Potential Local Marker of Renal Involvement in Scleroderma

    Edward Stern1,2, Cassandra Hong2, Voon H. Ong2, Aine Burns1, Robert Unwin3 and Christopher P. Denton4, 1Nephrology, Royal Free Hospital, London, United Kingdom, 2Rheumatology, UCL Division of Medicine, London, United Kingdom, 3Nephrology, UCL Division of Medicine, London, United Kingdom, 4Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom

    Background/Purpose: Renal disease in scleroderma (SSc), including scleroderma renal crisis (SRC), remains a major clinical challenge. Previous studies showed up to 50% of SSc patients…
  • Abstract Number: 1964 • 2015 ACR/ARHP Annual Meeting

    Biomarkers in Temporal Artery Biopsies and Sera of Patients with Giant Cell Arteritis

    Katja Lakota1, Tadeja Kuret2, Polona Žigon1, Ziga Rotar1, Matija Tomsic1, Saša Čučnik1,2, Snezna Sodin Semrl1,3 and Alojzija Hocevar1, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia, 3Faculty of Mathematics, Natural Science and Information Technology, University of Primorska, Koper, Slovenia

    Background/Purpose: Giant cell arteritis (GCA) is a large- and medium- vessel arteritis characterized by a range of histological patterns of vascular wall injury. The temporal…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology